$ADMA
ADMA BIOLOGICS, INC. Stock $adma

$adma Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000114036122040738 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$49.98M	$41.09M	$20.68M
YoY Change	89.45%	98.69%	101.24%
Cost Of Revenue	$35.80M	$31.43M	$20.30M
YoY Change	56.55%	54.88%	71.19%
Gross Profit	$14.18M	$9.657M	$385.3K
YoY Change	303.73%	2406.01%	-124.4%
Gross Profit Margin	28.36%	23.5%	1.86%
Selling, General & Admin	$18.98M	$12.89M	$13.87M
YoY Change	20.18%	-7.06%	34.3%
% of Gross Profit	133.9%	133.52%	3600.2%
Research & Development	$1.074M	$1.042M	$770.6K
YoY Change	47.37%	35.22%	-54.9%
% of Gross Profit	7.58%	10.79%	199.97%
Depreciation & Amortization	$1.937M	$1.700M	$1.200M
YoY Change	27.62%	41.67%	33.33%
% of Gross Profit	13.66%	17.6%	311.41%
Operating Expenses	$20.24M	$18.97M	$14.82M
YoY Change	21.15%	28.0%	-38.44%
Operating Profit	-$6.059M	-$9.317M	-$14.44M
YoY Change	-54.07%	-35.47%	4.61%
Interest Expense	-$5.735M	$5.580M	-$3.294M
YoY Change	73.07%	-269.39%	-206.57%
% of Operating Profit
Other Income/Expense, Net	-$438.5K	-$5.583M	$18.55K
YoY Change	202.8%	-30195.8%	-100.6%
Pretax Income	-$12.23M	-$14.90M	-$17.71M
YoY Change	-26.53%	-15.88%	4.69%
Income Tax
% Of Pretax Income
Net Earnings	-$12.23M	-$14.90M	-$17.71M
YoY Change	-26.53%	-15.88%	4.7%
Net Earnings / Revenue	-24.47%	-36.26%	-85.65%
Basic Earnings Per Share		-$0.08	-$0.13
Diluted Earnings Per Share	-$0.06	-$0.08	-$132.4K
COMMON SHARES
Basic Shares Outstanding	196.8M	196.4M	132.8M
Diluted Shares Outstanding		196.4M	133.8M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.52M	$34.91M	$34.41M
YoY Change	69.35%	1.44%	-42.36%
Cash & Equivalents	$86.52M	$34.91M	$34.41M
Short-Term Investments
Other Short-Term Assets	$5.095M	$5.372M	$5.859M
YoY Change	17.42%	-8.3%	54.19%
Inventory	$163.3M	$162.9M	$114.1M
Prepaid Expenses
Receivables	$15.51M	$20.90M	$20.39M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$270.4M	$224.1M	$174.8M
YoY Change	29.55%	28.21%	25.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.26M	$56.95M	$48.39M
YoY Change	14.38%	17.67%	22.14%
Goodwill	$3.500M	$3.530M	$3.500M
YoY Change	-0.84%	0.84%	-0.84%
Intangibles	$1.013M	$1.192M
YoY Change	-41.38%
Long-Term Investments
YoY Change
Other Assets	$4.770M	$4.459M	$3.334M
YoY Change	17.28%	33.77%	75.45%
Total Long-Term Assets	$78.06M	$76.46M	$63.86M
YoY Change	15.6%	19.74%	26.63%
TOTAL ASSETS
Total Short-Term Assets	$270.4M	$224.1M	$174.8M
Total Long-Term Assets	$78.06M	$76.46M	$63.86M
Total Assets	$348.5M	$300.6M	$238.6M
YoY Change	26.14%	25.95%	25.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.23M	$25.20M	$17.28M
YoY Change	6.44%	45.8%	116.58%
Accrued Expenses	$24.10M	$16.99M	$13.03M
YoY Change	43.5%	30.42%	61.36%
Deferred Revenue	$142.8K	$142.8K
YoY Change	0.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$39.27M	$44.44M	$32.34M
YoY Change	29.26%	37.43%	96.3%
LONG-TERM LIABILITIES
Long-Term Debt	$142.8M	$141.4M	$94.36M
YoY Change	50.56%	49.81%	-2.72%
Other Long-Term Liabilities	$350.5K	$362.2K	$9.160M
YoY Change	-11.8%	-96.05%	13408.72%
Total Long-Term Liabilities	$350.5K	$362.2K	$103.5M
YoY Change	-11.8%	-99.65%	152570.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.27M	$44.44M	$32.34M
Total Long-Term Liabilities	$350.5K	$362.2K	$103.5M
Total Liabilities	$196.5M	$200.2M	$135.9M
YoY Change	45.46%	47.34%	14.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$478.0M	-$465.8M
YoY Change	15.99%
Common Stock	$22.18K	$19.68K
YoY Change	13.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$152.0M	$100.4M	$102.8M
YoY Change
Total Liabilities & Shareholders Equity	$348.5M	$300.6M	$238.6M
YoY Change	26.14%	25.95%	25.62%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$12.23M	-$14.90M	-$17.71M
YoY Change	-26.53%	-15.88%	4.7%
Depreciation, Depletion And Amortization	$1.937M	$1.700M	$1.200M
YoY Change	27.62%	41.67%	33.33%
Cash From Operating Activities	-$7.379M	-$13.28M	-$13.41M
YoY Change	-77.95%	-0.95%	-43.76%
INVESTING ACTIVITIES
Capital Expenditures	$3.749M	-$3.380M	-$2.789M
YoY Change	-201.98%	21.22%	-3.51%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$3.749M	-$3.380M	-$2.789M
YoY Change	1.98%	21.22%	-3.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	62.74M	-843.8K	8.203M
YoY Change	16.58%	-110.29%	-22.83%
NET CHANGE
Cash From Operating Activities	-7.379M	-13.28M	-13.41M
Cash From Investing Activities	-3.749M	-3.380M	-2.789M
Cash From Financing Activities	62.74M	-843.8K	8.203M
Net Change In Cash	51.62M	-17.51M	-7.998M
YoY Change	209.47%	118.91%	-50.35%
FREE CASH FLOW
Cash From Operating Activities	-$7.379M	-$13.28M	-$13.41M
Capital Expenditures	$3.749M	-$3.380M	-$2.789M
Free Cash Flow	-$11.13M	-$9.904M	-$10.62M
YoY Change	-62.64%	-6.77%	-49.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Trading Symbol TradingSymbol	ADMA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	141172566
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1641388
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	9569604
CY2022Q1	adma	Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount	-442636
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25007857
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	126933065
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1191047
CY2022Q2	adma	Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount	41321
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-13764906
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	114400527
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	88249426
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	781397
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	41912515
CY2021Q1	adma	Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount	-59311
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18379941
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	112504086
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	805189
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17189560
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-18905303
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	111593532
	adma	Number Of Additional Plasma Collections Centers In Operation And Collection Of Plasma NumberOfAdditionalPlasmaCollectionsCentersInOperationAndCollectionOfPlasma	2
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1550263
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4600000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3400000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1197337
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2105653
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	981721
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18378932
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	17214988
CY2021Q4	adma	Senior Notes Payable Before Debt Discount SeniorNotesPayableBeforeDebtDiscount	100000000
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	12408226
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5133761
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000
CY2022Q3	adma	Senior Notes Payable Before Debt Discount SeniorNotesPayableBeforeDebtDiscount	153773932
CY2022Q3	adma	Accrued Rebates Current AccruedRebatesCurrent	9112871
CY2021Q4	adma	Accrued Rebates Current AccruedRebatesCurrent	5040200
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2486555
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4739651
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2866982
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	4066109
CY2022Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes	141365706
CY2021Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	94866239
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	56-2590442
	dei	Entity Address Address Line1 EntityAddressAddressLine1	465 State Route 17
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ramsey
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07446
	dei	City Area Code CityAreaCode	201
	dei	Local Phone Number LocalPhoneNumber	478-5552
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	196777308
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67315677
CY2021Q4	adma	Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts	200000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	298064
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001368514
	adma	Number Of Remaining Plasma Collection Facilities Under Construction NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction	1
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36728
	dei	Entity Registrant Name EntityRegistrantName	ADMA BIOLOGICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Security12b Title Security12bTitle	Common Stock
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1313494
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8213602
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-17712954
CY2022Q3	adma	Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount	-429981
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-14899504
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	100384536
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	688274
CY2021Q3	adma	Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount	-2287
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	102780167
CY2022Q3	adma	Accrued Testing Current AccruedTestingCurrent	256608
CY2021Q4	adma	Accrued Testing Current AccruedTestingCurrent	1189970
CY2021Q4	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	10000000
CY2022Q3	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	10000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	196776871
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	195813817
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	49951243
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	53271886
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1313494
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	688274
	us-gaap	Share Based Compensation ShareBasedCompensation	4145929
	us-gaap	Share Based Compensation ShareBasedCompensation	2274860
CY2021	adma	Number Of Fda Inspections NumberOfFDAInspections	2
	adma	Plasma Supply Agreement Term PlasmaSupplyAgreementTerm	P10Y
	adma	Plasma Purchased PlasmaPurchased	40300000
	adma	Percentage Of Inventory Purchases PercentageOfInventoryPurchases	0.68
	adma	Plasma Purchased PlasmaPurchased	31200000
	adma	Percentage Of Inventory Purchases PercentageOfInventoryPurchases	0.69
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000
	adma	Number Of Plasma Collection Facilities NumberOfPlasmaCollectionFacilities	10
	adma	Number Of Fda Licensed Plasma Collection Facilities NumberOfFDALicensedPlasmaCollectionFacilities	7
	adma	Number Of Additional Plasma Collections Centers In Operation And Collection Of Plasma NumberOfAdditionalPlasmaCollectionsCentersInOperationAndCollectionOfPlasma	2
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41090137
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	31433496
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9316733
CY2022Q3	adma	Interest And Other Nonoperating Income Expense InterestAndOtherNonoperatingIncomeExpense	-5582771
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-14899504
CY2022Q3	us-gaap	Assets Assets	300557570
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1861992
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20680550
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	20295213
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14437076
CY2021Q3	adma	Interest And Other Nonoperating Income Expense InterestAndOtherNonoperatingIncomeExpense	-3275878
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-17712954
CY2021Q3	us-gaap	Assets Assets	238640406
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1422164
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104098237
	us-gaap	Cost Of Revenue CostOfRevenue	83010156
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54559758
	us-gaap	Cost Of Revenue CostOfRevenue	56897959
	us-gaap	Operating Income Loss OperatingIncomeLoss	-45182557
	adma	Interest And Other Nonoperating Income Expense InterestAndOtherNonoperatingIncomeExpense	-9815641
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33306538
	adma	Interest And Other Nonoperating Income Expense InterestAndOtherNonoperatingIncomeExpense	-13695788
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6669941
	us-gaap	Net Income Loss NetIncomeLoss	-53672267
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10162650
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5176492
	us-gaap	Net Income Loss NetIncomeLoss	-54998198
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9835404
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3977786
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41090137
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20680550
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104098237
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54559758
	adma	Operating Lease Incremental Borrowing Rate Percent OperatingLeaseIncrementalBorrowingRatePercent	0.13
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1500000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1000000
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	500000
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	300000
	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000
	us-gaap	Operating Lease Payments OperatingLeasePayments	1100000
CY2022Q3	adma	Operating And Financing Lease Liability OperatingAndFinancingLeaseLiability	11400000
CY2021Q4	adma	Operating And Financing Lease Liability OperatingAndFinancingLeaseLiability	8100000
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y9M18D
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	480854
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2247057
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	19472954
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8116116
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	720755
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10636083
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2223314
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2246432
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1996036
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2040690
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	8238571
CY2022Q3	adma	Operating Lease Liabilities Additional Payment From Amendment OperatingLeaseLiabilitiesAdditionalPaymentFromAmendment	500000
	us-gaap	Interest Paid Net InterestPaidNet	9610361
	us-gaap	Interest Paid Net InterestPaidNet	8346968
	adma	Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities	1749746
	adma	Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities	1382818
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3660890
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2844875
	adma	Warrants Issued In Connection With Notes Payable WarrantsIssuedInConnectionWithNotesPayable	9569604
	adma	Warrants Issued In Connection With Notes Payable WarrantsIssuedInConnectionWithNotesPayable	0

Files In Submission

Name	View Source	Status
adma-20220930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
adma-20220930_lab.xml	Edgar Link	unprocessable
0001140361-22-040738-index-headers.html	Edgar Link	pending
0001140361-22-040738-index.html	Edgar Link	pending
0001140361-22-040738.txt	Edgar Link	pending
0001140361-22-040738-xbrl.zip	Edgar Link	pending
adma-20220930.xsd	Edgar Link	pending
brhc10043861_10q.htm	Edgar Link	pending
brhc10043861_ex10-1.htm	Edgar Link	pending
adma-20220930_cal.xml	Edgar Link	unprocessable
adma-20220930_pre.xml	Edgar Link	unprocessable
brhc10043861_10q_htm.xml	Edgar Link	completed
brhc10043861_ex31-1.htm	Edgar Link	pending
brhc10043861_ex31-2.htm	Edgar Link	pending
brhc10043861_ex32-1.htm	Edgar Link	pending
brhc10043861_ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADMA
ADMA BIOLOGICS, INC. Stock $adma

2022 Q4 Form 10-Q Financial Statement

#000114036122040738 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADMA ADMA BIOLOGICS, INC. Stock $adma

2022 Q4 Form 10-Q Financial Statement

#000114036122040738 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADMA
ADMA BIOLOGICS, INC. Stock $adma